Company: MBIO
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001410578-25-000085
Chunk: 265

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-07
Form: 424B4
Chunk 265
---
 for sale is immaterial to the results of operations. The assets held for sale were part of the repurchase of assets from uBriGene (see Note 5). Impairment of Long-Lived Assets The Company reviews long-lived assets, including tangible assets and other intangible assets with definitive lives, for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. The Company conducts its long-lived asset impairment analyses in accordance with ASC 360-10, “Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires the Company to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset group is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals.

F-36

Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies previously disclosed in the 2023 Form 10-K. Recently Issued Accounting Standards As of September 30, 2024, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2023 Form 10-K that affect the Company’s present or future results of operations, overall financial condition, liquidity, or disclosures upon adoption. Note 3 - Clinical Trial and Sponsored Research Agreements Research and Development Expenses – Clinical Trial and Sponsored Research Agreements For the three and nine months ended September 30, 2024 and 2023, the Company recorded the following expenses in research and development for sponsored research and clinical trial agreements in the Unaudited Statements of Operations pursuant to the terms of these agreements:

| ​                                                
 ​                                                
 ($ in thousands)                                 
 City of Hope National Medical Center             | ​ 
 ​ 
 ​ | ​                                        
 For the three months ended September 30, 
 2024                                     
 ​                                        |  ​ 
  ​ | ​ 
 ​ | ​    
 2023 
 ​    |    ​ 
    ​ | ​ 
 ​ 
 ​ | ​                                       
 For the nine months ended September 30, 
 2024                                    
 ​                                       |    ​ 
    ​ | ​ 
 ​ | ​    
 2023 
 ​    |     ​ 
     ​ |